We found no evidence to support short-term or prolonged feeding with a hydrolysed formula compared with exclusive breast feeding for prevention of allergic disease .
Very low- quality evidence indicates that short-term use of an EHF compared with a CMF may prevent infant CMA .
Further trials are recommended before implementation of this practice .We found no evidence to support prolonged feeding with a hydrolysed formula compared with a CMF for prevention of allergic disease in infants unable to be exclusively breast fed
BACKGROUND Infant formulas containing hydrolysed proteins have been widely advocated for preventing allergic disease in infants , in place of st and ard cow 's milk formula ( CMF ) .
However , it is unclear whether the clinical trial evidence supports this .
OBJECTIVES To compare effects on allergic disease when infants are fed a hydrolysed formula versus CMF or human breast milk .
If hydrolysed formulas are effective , to determine what type of hydrolysed formula is most effective , including extensively or partially hydrolysed formula ( EHF/PHF ) .
To determine whether infants at low or high risk of allergic disease , and whether infants receiving early short-term ( first few days after birth ) or prolonged formula feeding benefit from hydrolysed formulas .
Removal of Bovine Insulin From Cow's Milk Formula and Early Initiation of Beta-Cell Autoimmunity in the FINDIA Pilot Study.
OBJECTIVE To test whether weaning to a bovine insulin-free cow 's milk formula ( CMF ) reduces type 1 diabetes mellitus-associated autoantibodies in children at genetic risk . DESIGN R and omized , double-blind pilot trial ( Finnish Dietary Intervention Trial for the Prevention of Type 1 Diabetes [ FINDIA ] ) . SETTING Three pediatric hospitals in Finl and from May 15 , 2002 , to November 22 , 2005 . PARTICIPANTS A total of 1113 infants with HLA-conferred susceptibility to type 1 diabetes were r and omly assigned to receive study infant formulas ; 908 children provided at least 1 follow-up blood sample ( last follow-up , June 2009 ) . INTERVENTION The CMF ( n = 389 ) , whey-based hydrolyzed formula ( WHF ) ( n = 350 ) , or whey-based FINDIA formula essentially free of bovine insulin ( n = 365 ) during the first 6 months of life whenever breast milk was not available . MAIN OUTCOME MEASURES Primary outcome was beta-cell autoimmunity monitored at ages 3 , 6 , and 12 months and then annually until age 3 years . Autoantibodies to insulin , the 65-kDa isoform of glutamic acid decarboxylase , and the tyrosine phosphatase-related IA-2 molecule were screened , and islet cell autoantibodies and autoantibodies to zinc transporter 8 were analyzed in infants whose primary screening test results were positive . RESULTS In the intention-to-treat analysis , 6.3 % of children in the CMF group , 4.9 % of those in the WHF group , and 2.6 % of children in the FINDIA group were positive for at least 1 autoantibody by age 3 years . The odds ratios were 0.75 ( 95 % CI , 0.37 - 1.54 ) in the WHF group and 0.39 ( 0.17 - 0.91 ) in the FINDIA group when compared with the CMF group . In the treatment-received analysis , the corresponding odds ratios were 0.81 ( 95 % CI , 0.37 - 1.76 ) and 0.23 ( 0.08 - 0.69 ) . CONCLUSION In comparison with ordinary CMF , weaning to an insulin-free CMF reduced the cumulative incidence of autoantibodies by age 3 years in children at genetic risk of type 1 diabetes mellitus . TRIAL REGISTRATION clinical trials.gov Identifier : NCT01055080
We found no evidence to support short-term or prolonged feeding with a hydrolysed formula compared with exclusive breast feeding for prevention of allergic disease .
Very low- quality evidence indicates that short-term use of an EHF compared with a CMF may prevent infant CMA .
Further trials are recommended before implementation of this practice .We found no evidence to support prolonged feeding with a hydrolysed formula compared with a CMF for prevention of allergic disease in infants unable to be exclusively breast fed
BACKGROUND Infant formulas containing hydrolysed proteins have been widely advocated for preventing allergic disease in infants , in place of st and ard cow 's milk formula ( CMF ) .
However , it is unclear whether the clinical trial evidence supports this .
OBJECTIVES To compare effects on allergic disease when infants are fed a hydrolysed formula versus CMF or human breast milk .
If hydrolysed formulas are effective , to determine what type of hydrolysed formula is most effective , including extensively or partially hydrolysed formula ( EHF/PHF ) .
To determine whether infants at low or high risk of allergic disease , and whether infants receiving early short-term ( first few days after birth ) or prolonged formula feeding benefit from hydrolysed formulas .